NCT02345707 - Relative Bioavailability Study of Phase III Tablet Formulation of Cabotegravir | Biotech Hunter

Enrollment

Participants

Timeline

Start Date

March 31, 2015

Primary Completion Date

June 30, 2015

Study Completion Date

June 30, 2015

Conditions

Infection, Human Immunodeficiency Virus

Interventions

DRUG

Cabotegravir 30 mg current formulation

Cabotegravir 30 mg current formulation (Treatment A) is a film coated tablet with a weight of 824 mg

DRUG

Cabotegravir 30 mg micronized new formulation 500 M

Cabotegravir 30 mg micronized new formulation 500 M (Treatment B) is a film coated tablet with a weight of 515 mg

DRUG

Cabotegravir 30 mg unmicronized new formulation 500 U

Cabotegravir 30 mg unmicronized new formulation 500 U (Treatment C) is a film coated tablet with a weight of 515 mg

DRUG

Cabotegravir 30 mg micronized new formulation 650 M

Cabotegravir 30 mg micronized new formulation 650 M (Treatment D) is a film coated tablet with a weight of 670 mg

DRUG

Cabotegravir 30 mg unmicronized new formulation 650 U

Cabotegravir 30 mg unmicronized new formulation 650 U (Treatment E) is a film coated tablet with a weight of 670 mg

Trial Locations (1)

GSK Investigational Site, Overland Park